behind it. Discussions on April 23, 1980, between our medical personnel (Department of Energy and Brookhaven National Laboratory) and Mr. Copaken's medical consultant, Dr. Robert G. Loeffler, were most helpful in clarifying many of these issues, however. It presumably is a consequence of these discussions that Mr. Copaken verbally requested us to amplify upon our offer of March 25, 1980.

This amplification basically consists of a detailed identification of the laboratory tests to be included under the general term "biochemical screening profile" which was included in paragraph 1 of the proposed agreement appended to my letter of March 25, 1980. The identification of specific tests included under that term is appended to this letter. You will note that it includes hematological, biochemical and urological analyses, plus other indicators, which would clearly identify, among other things, any evidence of thyroid dysfunction or of blood dyscrasias.

Clearly, any possible radiation exposure of the people of Likiep Atoll has been considerably less than that experienced by the people of Rongelap and Utirik, and, at this time, after 26 years of medical follow-up, we have no reason to believe that diseases which have not appeared among the Rongelap and Utirik populations would appear among any other populations in the Marshall Islands as a consequence of any possible lower levels of radiation exposure (e.g., bone cancer or opthalmic effects).

DOCUMENT DOES NOT CONTAIN ECI

= = =

Reviewed by Park Kusher Date 5/1/97

Except for the enclosed clarification of the first paragraph as indicated, the proposed agreement included in my letter to Mrs. Van Cleve of March 25, 1980, remains valid.

We hope that this will clarify our previous proposal and will be responsive to your request and that of Mr. Copaken.

Sincerely,

15/

Bruce W. Wachholz, Ph.D.
Office of Health and Environmental
Research, Office of Environment

Enclosure

bcc: OHER Reading File
Wachholz's Reading File
L. Brothers, DASEV/P, EV-2

BWachhol₂ DETIALS/SIG. DATE 6/ /80 ATO SYMBOL TMcCraw METIALS/SIGL 6/ /80 RYOL SYMBOL JViren METIALS/SIGL DATE 6/ /80 ATG. SYMBOL JBlair PHITIALS/SIG. 6/ /80 RTG. SYMBOL WWBurr-PHTIALS/SIG. DATE 11 6/ /80 RTG. SYMBOL HHollister METIALS/SIG. 6/ /80 RTG. SYMBOL RCClusen NETIALS/SIGL DATE 6/ /80

RTG. SYMBOL

NTIALS/SIG.

RTG. SYMBOL

BUTIALS/SKL

CONCURRENCES

ATOL SYMBOL

STUDIES TO BE INCLUDED PER THE PROPOSED AGREEMENT OF MARCH 25, 1980

- I. Medical History
- II. Clinical Studies
- III. Laboratory Tests
 - A. Hematological Analyses
 - 1. White Blood Cell
 - 2. Red Blood Cell
 - 3. Hematocrit
 - 4. Hemoglobin
 - 5. Platelet
 - 6. Differential Count
 - 7. Computation of Cell Indices
 - 8. Cellular Morphology
 - B. Biochemical Analyses
 - 1. T₄
 - 2. TSH

As indicated to follow thyroid carcinoma

- 3. HTG_
- 4. SMA-20, including
 - a. Sugar
 - b. Electrolytes
 - c. Lipids
 - d. Serum protein
 - e. Uric acid
 - f. Blood urea nitrogen

- g. Creatinine
- h. LDH
- 1. CPK
- j. And such other tests as may be indicated by disease patterns (e.g., alkaline phosphatase, cholesterol, etc.)
- C. Urinalysis, Including Routine Microscopic Analysis

IV. Other

Where confirmatory evidence is indicated (e.g., gamma camera imaging, biopsies), such tests would be recommended on a case-by-case basis.

11

: :